General background text Pharmacogenetics –
Dihydropyrimidine dehydrogenase (DPD)

Last updated: 9 May 2019

Definitions in pharmacogenetics

The **genotype** is the hereditary information about a specific characteristic of an individual. This information is located in the genes, in the DNA that consists of nucleotides. The piece of the DNA that carries information for one specific hereditary characteristic is called a **gene.** The DNA is divided into chromosomes, which usually occur in pairs. A person generally has two copies (**alleles**) of a gene, one on each of the chromosomes of a chromosome pair.

The **phenotype** indicates what the final manifestation (phenotypic state) of a certain genotype is. This can involve the functionality of a protein (for example the enzyme or the receptor), but also the physical manifestation of a disease. The phenotype is a result of the genotype that a person possesses, the degree of expression of the gene in question and the combination with environmental factors such as co-medication, diet and disease conditions.

Variations can exist in a population within the DNA that encodes a protein. Variations can result in alleles that encode for proteins with no or reduced activity. The simplest form of variations are **"single-nucleotide polymorphisms" (SNPs)**, in which a certain part of a gene differs by only one nucleotide. If a gene variation occurs in at least 1% of the population, then this is referred to as a genetic **polymorphism. Wild-type** is the name given to the most common active allele. There can be a number of different polymorphisms for a certain allele.

Names of genes are given in italics. In some cases the abbreviation of the name of the gene can differ from the name of the gene product. This is the case for dihydropyrimidine dehydrogenase, where the gene is abbreviated to *DPYD* and the enzyme to DPD.

Altered metabolic capacity and clinical consequences

Fluorouracil is mainly (> 80%) converted by dihydropyrimidine dehydrogenase (DPD) to the inactive metabolite dihydrofluorouracil. DPD is mainly present in the liver, but also in most other tissues. Lower metabolic activity of DPD leads to increased intracellular concentrations of fluorodeoxyuridine monophosphate, the active metabolite of fluorouracil and its prodrug capecitabine. This leads to an increased risk of side effects such as neutropenia, thrombopenia and "hand-foot" syndrome.

Variations in the gene that encodes the DPD enzyme can result in reduced or absent enzyme activity.

The population can be divided into five phenotypes (ranked below according to decreasing activity), based on the metabolic capacity of DPD that is present and the therapy that needs to be implemented:

- Gene activity score 2 (AS 2): "normal" metabolic capacity (normal metaboliser (NM), two fully active alleles)
- Gene activity score 1.5 (AS 1.5): reduced metabolic capacity (one fully active and one reduced-activity allele)
- Gene activity score 1 (AS 1): halved metabolic capacity caused by a single gene variation (one fully active and one inactive allele)
- Phenotyping (PHENO): strongly reduced metabolic capacity (two reduced-activity alleles or one inactive and one reduced-activity allele, or more commonly two gene variations that result in a reduced-activity allele or one gene variation that results in one inactive allele and one gene variation that results in a reduced-activity allele)
- Gene activity score 0 (AS 0): absent metabolic capacity (two inactive alleles, or more commonly two gene variations resulting in an inactive allele)

There is also variation in metabolic capacity within a group with a certain gene activity score.

As the genotype only determines part of the metabolic capacity, the guidelines for dose adjustment based on the genotype are no more than a tool that can be used to achieve the desired intracellular concentration of the active metabolite. Pharmacokinetic dose adjustment (guided by plasma concentrations or AUC) may be useful

for fluorouracil to optimise the dose. Although capecitabine is largely converted to fluorouracil in tissue, pharmacokinetic dose adjustment (based on the plasma concentrations or AUC of fluorouracil) can also be implemented for capecitabine.

Genotyping

The process of genotyping is used to determine the genotype. It indicates which variations of the gene for DPD are present in the tested individual. In the past, gene variations were assigned a name that consists of a star (*) and a number, an example of a possible DPD genotype is *DPYD*1/*2A*. However, this nomenclature is not available for gene variations discovered at a later stage. This is why some alleles are still referred to by nucleotide numbers followed by nucleotide changes (or by amino acid number preceded by symbol of the amino acid in the wild-type protein followed by the symbol of the amino acid in the variant).

Many variations exist for DPD; more than 30 different gene variations have been identified and described in the literature. The incidences of all variations that result in reduced DPD activity are low and whether DPD activity is affected is not fully known for each variant; a reliable genotyping test for DPD is not available. A number of these alleles are listed in Table 1, including their functionality. Genotyping usually screens for only the most common and best substantiated variant alleles. Currently, these variants are *2A, *13, 2846A>T and 1236G>A. This may result in less common variants being missed and incorrectly being designated the wild-type.

Table 1. *DPYD* gene variations and metabolic capacity

Metabolic capacity	strong evidence for functionality (or by definition in the case of *1)	moderate evidence for functionality (*in vitro* and clinical/*ex vivo* data)	weak evidence for functionality (*in vitro* data only and/or limited clinical/*ex vivo* data)
Fully functional (wild-type; gene activity score 1)	*1 *5 = 1627A>G *9A = 85T>C	*4 = 1601G>A *6 = 2194G>A *9B = 85T>C + 2657G>A *11 = 1003G>T 62G>A 496A>G IVS10-15T>C 1896C>T	
Reduced functionality (gene activity score 0.5)	1236G>A / 1129-5923C>G (hapB3)$ 2846A>T		
fully dysfunctional (inactive or null allele; gene activity score 0)	*2A = IVS14+1G>A *13 = 1679T>G%	*3 = 1897delC *7 = 295-298delTCAT *8 = 703C>T *10 = 2983G>T *12 = 1156G>T	257C>T& 300C>A& 1651G>A 1024G>A& 1025A>G& 1475C>T& 1774C>T& Duplication of exons 17+18%

$ Variant 1236G>A, which does not result in a change in amino acids, is in complete linkage disequilibrium with variant 1129-5923C>G, which results in abnormal splicing of a part of the mRNA, resulting in the formation of a premature stop codon. The resulting DPD activity accounts for approximately half of the normal activity. Both variants are part of haplotype B3.

% For these variants, there is limited evidence from studies or from a case report that measured DPD activity, that the variants (amino acid substitution (Ile560Ser) for *13) lead to an inactive enzyme.

& These variants were found in a case study involving toxicity and have a very low enzyme activity *in vitro*.

Translation from genotype to phenotype

When an individual's genotype has been determined and one wants to know what the metabolic capacity for DPD is, then the genotype needs to be "translated" to the phenotype. If two gene variations are present that do not both result in an inactive allele, then this should be translated in the phenotype "phenotyping" ("PHENO"). If

this is not the case, then the gene activity scores of both gene variants (both alleles) should be added together in the translation from the genotype to the phenotype (see table 2). If there are more than two gene variations, then the genotype should be translated into a "gene activity score 0" ('AS 0') if two or more of these gene variations result in an inactive allele and to "phenotyping" ("PHENO") if this is not the case. In rare cases involving two different gene variations, the variations can be located on the same allele instead of on different alleles. As it is always recommended to determine the DPD activity in the case of two or more gene variations and adjust the dose accordingly, this does not need to be taken into consideration when translating the genotyping result into the predicted phenotype.

Table 2. Relationship between genotyping result and predicted phenotype

Genotyping result	Predicted phenotype
No gene variant resulting in decreased DPD activity (*1/*1)	Gene activity score 2 (normal metaboliser)
One reduced functional gene variant (*1/1236A or *1/2846T)	Gene activity score 1.5
One fully dysfunctional gene variant (*1/*2A or *1/*13)	Gene activity score 1
Two reduced functional gene variants or one fully dysfunctional gene variant and one reduced functional gene variant (1236A/1236A, 2846T/2846T, both 1236A and 2846T, both *2A and 1236A, both *2A and 2846T, both *13 and 1236A or both *13 and 2846T)	Phenotyping
Two fully dysfunctional gene variants (*2A/*2A, *13/*13 or both *2A and *13)	Gene activity score 0

Phenotyping
The process of phenotyping is used to determine the phenotype, which means: measuring or estimating the activity of the DPD enzyme.
Possible phenotyping methods are analysing DPD enzyme activity in peripheral mononuclear blood cells [Kuilenburg, 2000] or measuring uracil concentration in plasma or urine [Ploylearmsaeng, 2006], with the first method being the most reliable. Depending on the exact method used for the determination, the average Caucasian DPD enzyme activity is 9.9 ± 2.8 nmol/hour per mg protein [Kuilenburg, 2002] or 9.6 ± 2.2 nmol/hour per mg protein [Pluim, 2015].
Methods that are less commonly used nowadays are the 2-^{13}C-uracil breath test [Mattison, 2004] or analysis of plasma uracil/dihydrouracil ratios [Ciccolini, 2006; Zhou, 2007]. The first test measures $^{13}CO_2$ formation following breakdown of 2-^{13}C-uracil mediated by DPD and other enzymes in the pyrimidine catabolic route. The second test measures conversion of the endogenous uracil substrate. The activity of the DPD enzyme can also be determined by analysing conversion of a single dose of uracil [van Staveren, 2013].
All existing phenotyping methods have limited applicability for either accuracy or sensitivity reasons or because of the feasibility of screening large numbers of patients (costs and time commitment).

Ethnic variation in prevalence of phenotypes and allele frequency
In the Caucasian population, approximately 3-5% have partial DPD deficiency and 0.1-0.2% have complete DPD deficiency. Approximately 8% of the African American population have partial DPD deficiency.
The frequency of occurrence of the various DPD alleles and the different phenotypes appears to vary significantly between nations and ethnic groups. In the Dutch population, the most common reduced-functional allele contains the gene variant 1236A and the most common fully dysfunctional allele contains the gene variant *2A.
Allele frequencies and phenotypes per population are given in table 5.

Table 5. Ethnic variation in prevalence of phenotypes and gene variant frequency

Ethnicity	Country	Prevalence of phenotype (%)			Gene variant frequency (%)			
		PM[#]	IM[#]	NM[#]	*2A	2846 A>T	1236 G>A	*13
Caucasian		0.1-0.2	3-5	95-97	0-1.4	1	0.3-3.7	0.1
	The Netherlands				0.6	0.7	2.5-3.7	
Asian	South West Asia				0-0.75			
	East Asia				0-2.7	0		

African-American			8		0			

#: PM (poor metaboliser), IM (intermediate metaboliser) and NM (normal metaboliser) in the table above mean the following:
   PM: 0 fully functional alleles (gene activity score 0 or phenotyping)
   IM: 1 fully functional allele (gene activity score 1 or 1.5)
   NM: 2 fully functional alleles (gene activity score 2)

Literature

- Mattison LK et al. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004;10:2652–8.
- Ciccolini J et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006;28:678–85.
- Ploylearmsaeng SA et al. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45:567-92.
- Van Kuilenburg AB et al. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000;46:9-17.
- Zhou ZW et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007;53:127–131.
- van Staveren MC et al. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 2013;13:389-95.
- Tuchman M et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985;313:245–9.
- Mattison LK et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491–5.
- Van Kuilenburg ABP et al. Lethal outcome of patient with complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin Cancer Res 2001;7:1149–53.
- Sulzyc-Bielicka V et al. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep 2008;60:238-42.
- Morel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.
- Seck K et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005 Aug 15;11(16):5886-92.
- Yamaguchi K et al. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001;92:337-42.
- Deenen MJ et al. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 2010;153:767-8.
- Rosmarin D et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 2015;64:111-20.
- Deenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011;17:3455-68.
- Kristensen MH et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res 2010;38:870-83.
- Lunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. Pharmacogenomics 2016;17:721-9.
- Henricks LM et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer 2018;142:424-30.
- Van Kuilenburg et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002;101:253-8.
- Pluim D et al: Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis 2015;7:519-29.
- Henricks LM et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:1459-67 en persoonlijke communicatie (getitreerde dosis en mediane DPD-activiteit).
- van Kuilenburg ABP et al. Dihydropyrimidine dehydrogenase deficiency: homozygosity for an extremely rare variant in DPYD due to uniparental isodisomy of chromosome 1. JIMD Rep 2019;45:65-9.
- https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/, geraadpleegd op 26-2-2019.